Total Clarity Wealth Management Inc. Acquires Shares of 16,450 uniQure (NASDAQ:QURE)

Total Clarity Wealth Management Inc. bought a new stake in uniQure (NASDAQ:QURE) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,450 shares of the biotechnology company’s stock, valued at approximately $74,000.

A number of other large investors also recently made changes to their positions in the company. Vestal Point Capital LP purchased a new stake in uniQure in the 4th quarter valued at about $26,572,000. Vanguard Group Inc. lifted its holdings in uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after acquiring an additional 109,740 shares during the period. BNP Paribas Financial Markets boosted its position in uniQure by 4.3% in the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock worth $3,831,000 after purchasing an additional 30,054 shares during the last quarter. Privium Fund Management B.V. grew its stake in uniQure by 10.6% in the 2nd quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock valued at $2,869,000 after purchasing an additional 61,501 shares during the period. Finally, Acadian Asset Management LLC increased its position in shares of uniQure by 133.1% during the 1st quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after purchasing an additional 350,291 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on QURE shares. Cantor Fitzgerald restated an “overweight” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, July 16th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of uniQure in a report on Tuesday, August 20th. StockNews.com raised uniQure to a “sell” rating in a report on Monday, August 5th. Finally, The Goldman Sachs Group boosted their target price on uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $18.60.

uniQure Stock Down 4.4 %

QURE opened at $5.41 on Tuesday. The company has a 50 day moving average of $7.00 and a 200 day moving average of $5.63. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 1.06. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35. The company has a market cap of $262.65 million, a PE ratio of -0.87 and a beta of 0.95.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.08. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $3.47 million. On average, sell-side analysts expect that uniQure will post -4.04 EPS for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.